Clinical Trials Logo

Malignant Melanoma Stage IV clinical trials

View clinical trials related to Malignant Melanoma Stage IV.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04577729 Terminated - Clinical trials for Fecal Microbiota Transplantation

The IRMI-FMT Trial

Start date: May 21, 2021
Phase: N/A
Study type: Interventional

Aim of the study is to investigate the effect of Fecal Microbiota Transplantation (FMT) and Checkpoint Inhibitor (CI) re-challenge in prior CI refractory patients on Progression free survival (PFS) and tumor using donor stool of former malignant melanoma patients, who have been in remission due to CI treatment for at least 1 year.

NCT ID: NCT03430947 Terminated - Brain Metastases Clinical Trials

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

RadioCoBRIM
Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II, open label, non-randomised study of vemurafenib and cobimetinib after radiosurgery in adult patients with BRAFV600-mutant melanoma brain metastases. All patients will receive vemurafenib 960 mg twice a day on days 1 - 28 combined with cobimetinib 60 mg once a day on days 1 - 21 of each 28-day treatment cycle until disease progression, drug toxicity or death. The primary objective of this study is to determine the best overall response rate (BORR) in the brain. The extracranial BORR, intra- and extracranial duration of response, progression-free survival and overall survival, adverse events, quality of life and radiomics features predicting long-term local control of brain metastases and treatment-related toxicity will also be examined.

NCT ID: NCT00722098 Terminated - Clinical trials for Malignant Melanoma Stage IV

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the combination of chemotherapy (Cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.